Filing Details
- Accession Number:
- 0001179110-13-008495
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-15 18:51:11
- Reporting Period:
- 2013-05-13
- Filing Date:
- 2013-05-15
- Accepted Time:
- 2013-05-15 18:51:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1397266 | K Matthew Fust | C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080 | Evp & Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-05-13 | 10,269 | $34.48 | 60,473 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-05-13 | 4,269 | $97.54 | 56,204 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2013-05-13 | 6,000 | $98.70 | 50,204 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2013-05-13 | 10,269 | $0.00 | 10,269 | $34.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 41,450 | 2019-01-05 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- The shares were sold at prices ranging from $97.2301 to $98.1201. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The shares were sold at prices ranging from $98.45 to $98.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Fully vested.
Billionaire Hedge Funds
